Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-12-23 ms1000000382468845 来自重庆

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-12-19 1469407fm39暂无昵称来自石川县

审稿速度:24.0 | 投稿命中率:50.0
经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。

3 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-10-25 ms1000001788822128 来自北京

editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。

59 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-12-10 ms3000001788822132 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：实践综述，个人觉得审稿速度挺快的。
一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。
后面就是漫长的返修等待，最后在前天录用了
我是9月底投稿的总共耗时2个多月。

10 0

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-08-07 ms3000001758728711 来自河南省

各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭

235 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2023-04-13 14718874m55(暂无昵称) 来自辽宁省

纯SEER数据库还能投吗

92 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2023-08-17 ms2000001754372244 来自江西省

偏重的研究方向：非小细胞肺癌
经验分享：免疫组化预后预测模型可以投吗😭

123 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-09-19 ms1000001788820006 来自上海

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。

66 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-11-21 ms2000001788822130 来自上海

Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊
在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。
编辑和审稿人比较友好且专业。

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2244569, encodeId=2523224456950, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：我也是从投稿到现在已经4个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，还让我自己找编辑。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01bd6152710, createdName=ms1000000382468845, createdTime=Mon Dec 23 22:32:31 CST 2024, time=2024-12-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2243444, encodeId=8ee1224344404, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：从投稿到现在已经3个月，还没有给分配编辑，发邮件回复说没有找到合适的编辑，这都是借口。该期刊不知道遇到了什么困境，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca1e5149909, createdName=1469407fm39暂无昵称, createdTime=Thu Dec 19 09:27:09 CST 2024, time=2024-12-19, status=1, ipAttribution=石川县), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2241751, encodeId=c5a62241e5145, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实践综述，个人觉得审稿速度挺快的。 一审1个月左右就完成，我总共邀请了两位审稿人，两位都给了修改意见。 后面就是漫长的返修等待，最后在前天录用了 我是9月底投稿的总共耗时2个多月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 10 23:22:15 CST 2024, time=2024-12-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海)]

2024-10-13 ms1000001788822100 来自上海

投稿命中率:50.0
经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。
在系统中也没有看到 finalized或rejected
现在正在接受审稿人3审稿～

64 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务